Shares in medical diagnostics firm LungLife AI (LLAI) have taken a hit today on the back of news that results from its pivotal validation study would now be released in Q4, rather than by 30th September as originally planned.

To me, this looks like an over-reaction, since the delay is simply due to administrative issues involving the receipt of data from clinical sites, full database lock, and the knock-on impact to the analysis.

This minor setback might be a little frustrating for shareholders, but I suspect it is being far more intensely felt by CEO Paul Pagano and his team who are committed to completing the study and commercialising the proprietary science and AI software.

Remember too, that an influential industry journal, BMC Pulmonary Medicine, has already independently peer-reviewed its flagship circulating tumour cells and AI enhanced LungLB blood test in an earlier program, concluding that the cutting edge diagnostic had “outperformed other commonly used evaluation tools, including the Mayo Clinic risk model and PET scan.”